Against the odds, GSK has secured FDA approval for its multiple myeloma therapy Blenrep, three years after it was removed from sale. Anti-BCMA antibody-drug conjugate (ADC) Blenrep (belantamab ...
Thank you for submitting your question. Keep reading Forbes Advisor for the chance to see the answer to your question in one of our upcoming stories. Our editors also may be in touch with follow-up ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback